Concepedia

The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial

Sender Herschorn, Alfred Kohan, Philip J. Aliotta, Kurt McCammon, Sriram Rajagopalan, Steven Abrams, Wayne Lam, Karel Everaert

The Journal of Urology · 2017 · 39 citations · 18 references

DOI

Abstract

The efficacy of onabotulinumtoxinA and solifenacin was significantly higher than that of placebo. However, onabotulinumtoxinA showed significantly greater decreases in urinary incontinence than solifenacin with a third of patients achieving a 100% incontinence reduction. No unexpected safety signals were observed.

References

18

Prevalence and burden of overactive bladder in the United States

Walter F. Stewart, J. Van Rooyen, Geoffrey W. Cundiff et al. · World Journal of Urology · 2003 · 2.2K citations · Full text

, , +5

How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study

Ian Milsom, Paul Abrams, L. Cardozo et al. · British Journal of Urology · 2001 · 1.8K citations

Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction

Debra E. Irwin, Zoë Kopp, Barnabie Agatep et al. · British Journal of Urology · 2011 · 987 citations

OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial

Christopher R. Chapple, Karl‐Dietrich Sievert, Scott MacDiarmid et al. · European Urology · 2013 · 401 citations

, , +5

OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial

Victor W. Νitti, Roger R. Dmochowski, Sender Herschorn et al. · The Journal of Urology · 2012 · 399 citations